PLRX Pliant Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PLRX

Price (delayed)

$13.98

Market cap

$842.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.75

Enterprise value

$788.8M

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual ...

Highlights
Pliant Therapeutics's debt has decreased by 28% YoY and by 6% QoQ
The EPS has grown by 6% year-on-year
The equity has soared by 51% YoY but it has contracted by 6% from the previous quarter
The company's quick ratio rose by 25% YoY but it fell by 9% QoQ
PLRX's gross profit has dropped by 84% year-on-year and by 55% since the previous quarter
The revenue has dropped by 84% year-on-year and by 55% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://pliantrx.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of PLRX
Market
Shares outstanding
60.24M
Market cap
$842.14M
Enterprise value
$788.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.77
Price to sales (P/S)
519.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
499.24
Earnings
Revenue
$1.58M
EBIT
-$160.07M
EBITDA
-$155.84M
Free cash flow
-$117.28M
Per share
EPS
-$2.75
Free cash flow per share
-$2
Book value per share
$7.91
Revenue per share
$0.03
TBVPS
$8.72
Balance sheet
Total assets
$512.15M
Total liabilities
$38.58M
Debt
$11.37M
Equity
$473.58M
Working capital
$476.98M
Liquidity
Debt to equity
0.02
Current ratio
17.72
Quick ratio
17.38
Net debt/EBITDA
0.34
Margins
EBITDA margin
-9,863.2%
Gross margin
100%
Net margin
-10,211.1%
Operating margin
-11,654.7%
Efficiency
Return on assets
-29%
Return on equity
-31.2%
Return on invested capital
-33.9%
Return on capital employed
-33.1%
Return on sales
-10,130.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLRX stock price

How has the Pliant Therapeutics stock price performed over time
Intraday
5.51%
1 week
18.37%
1 month
-3.12%
1 year
-41.51%
YTD
-22.81%
QTD
-6.17%

Financial performance

How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$1.58M
Gross profit
$1.58M
Operating income
-$184.15M
Net income
-$161.34M
Gross margin
100%
Net margin
-10,211.1%
The operating margin has plunged by 137% from the previous quarter
Pliant Therapeutics's net margin has shrunk by 133% QoQ
PLRX's gross profit has dropped by 84% year-on-year and by 55% since the previous quarter
The revenue has dropped by 84% year-on-year and by 55% since the previous quarter

Growth

What is Pliant Therapeutics's growth rate over time

Valuation

What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
1.77
P/S
519.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
499.24
The EPS has grown by 6% year-on-year
The equity has soared by 51% YoY but it has contracted by 6% from the previous quarter
PLRX's price to book (P/B) is 27% lower than its last 4 quarters average of 2.3
The revenue has dropped by 84% year-on-year and by 55% since the previous quarter
The P/S is 48% more than the last 4 quarters average of 332.7

Efficiency

How efficient is Pliant Therapeutics business performance
The return on sales has dropped by 133% since the previous quarter
The ROE is up by 39% year-on-year and by 4% since the previous quarter
Pliant Therapeutics's return on assets has increased by 35% YoY and by 3.7% QoQ
The company's return on invested capital rose by 35% YoY and by 2.6% QoQ

Dividends

What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLRX.

Financial health

How did Pliant Therapeutics financials performed over time
The company's total assets rose by 46% YoY but it fell by 5% QoQ
The company's quick ratio rose by 25% YoY but it fell by 9% QoQ
Pliant Therapeutics's debt is 98% lower than its equity
PLRX's debt to equity has dropped by 60% year-on-year
The equity has soared by 51% YoY but it has contracted by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.